Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer.

ABSTRACT:

Importance

Surgery followed by adjuvant chemotherapy or chemoradiation is widely used to treat resectable pancreatic cancer. Although studies suggest initiation of adjuvant therapy within 12 weeks of surgery, there is no clear time interval associated with better survival.

Objective

To evaluate the ideal timing of adjuvant therapy for patients with stage I to II resected pancreatic cancer.

Design, setting, and participants

This cohort study included 7548 patients with stage I to II resected pancreatic cancer (5453 with adjuvant therapy; 2095 without adjuvant therapy) from the National Cancer Database from 2004 to 2015. Data were collected from January 2014 to December 2015 and analyzed from December 2018 to May 2019.

Exposures

Adjuvant chemotherapy or chemoradi

SUBMITTER: Ma SJ 

PROVIDER: S-EPMC6694394 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature